These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7995052)

  • 1. Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression.
    Fruehauf JP; Manetta A
    Contrib Gynecol Obstet; 1994; 19():39-52. PubMed ID: 7995052
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
    J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy?
    Ludwig AH; Kupryjañczyk J
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6204. PubMed ID: 17062699
    [No Abstract]   [Full Text] [Related]  

  • 7. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
    Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD; Li M; Yuan Y; Mao N; Pan LY
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.
    Xing H; Wang S; Weng D; Chen G; Yang X; Zhou J; Xu G; Lu Y; Ma D
    Oncol Rep; 2007 Jan; 17(1):117-22. PubMed ID: 17143487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
    Kavallaris M; Kuo DY; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB
    J Clin Invest; 1997 Sep; 100(5):1282-93. PubMed ID: 9276747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
    Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
    J Pharm Sci; 2008 Jun; 97(6):2045-8. PubMed ID: 17828752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity to taxoid derivatives of a newly established human endometrioid ovarian adenocarcinoma radioresistant cell line.
    Griffon G; Merlin JL; Parache RM; Martinet N; Marchal S; Nabet F; Wellman M; Barlier C; Marchal C
    Anticancer Res; 1996; 16(1):177-87. PubMed ID: 8615606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
    Li J; Liu P; Mao H; Wanga A; Zhang X
    Oncol Rep; 2009 Jun; 21(6):1605-10. PubMed ID: 19424643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay.
    Raspollini MR; Pinzani P; Pazzagli M; Baroni G; Taddei A; Amunni G; Villanucci A; Taddei GL
    J Chemother; 2002 Oct; 14(5):518-25. PubMed ID: 12462432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.